Logo image of BMEA

BIOMEA FUSION INC (BMEA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BMEA - US09077A1060 - Common Stock

1.41 USD
-0.11 (-7.24%)
Last: 12/12/2025, 8:16:12 PM
1.44 USD
+0.03 (+2.13%)
Pre-Market: 12/15/2025, 6:00:18 AM
Fundamental Rating

2

BMEA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 529 industry peers in the Biotechnology industry. The financial health of BMEA is average, but there are quite some concerns on its profitability. BMEA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BMEA had negative earnings in the past year.
BMEA had a negative operating cash flow in the past year.
In the past 5 years BMEA always reported negative net income.
BMEA had a negative operating cash flow in each of the past 5 years.
BMEA Yearly Net Income VS EBIT VS OCF VS FCFBMEA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -173.43%, BMEA is doing worse than 88.47% of the companies in the same industry.
BMEA has a worse Return On Equity (-612.79%) than 77.88% of its industry peers.
Industry RankSector Rank
ROA -173.43%
ROE -612.79%
ROIC N/A
ROA(3y)-98.37%
ROA(5y)-65.2%
ROE(3y)-137.7%
ROE(5y)-89.02%
ROIC(3y)N/A
ROIC(5y)N/A
BMEA Yearly ROA, ROE, ROICBMEA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 0 0 0 0

1.3 Margins

BMEA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BMEA Yearly Profit, Operating, Gross MarginsBMEA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for BMEA has been increased compared to 1 year ago.
BMEA has more shares outstanding than it did 5 years ago.
There is no outstanding debt for BMEA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BMEA Yearly Shares OutstandingBMEA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
BMEA Yearly Total Debt VS Total AssetsBMEA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -15.22, we must say that BMEA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -15.22, BMEA is not doing good in the industry: 80.53% of the companies in the same industry are doing better.
There is no outstanding debt for BMEA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -15.22
ROIC/WACCN/A
WACCN/A
BMEA Yearly LT Debt VS Equity VS FCFBMEA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M 150M

2.3 Liquidity

A Current Ratio of 3.18 indicates that BMEA has no problem at all paying its short term obligations.
The Current ratio of BMEA (3.18) is worse than 63.14% of its industry peers.
BMEA has a Quick Ratio of 3.18. This indicates that BMEA is financially healthy and has no problem in meeting its short term obligations.
BMEA has a Quick ratio of 3.18. This is in the lower half of the industry: BMEA underperforms 60.30% of its industry peers.
Industry RankSector Rank
Current Ratio 3.18
Quick Ratio 3.18
BMEA Yearly Current Assets VS Current LiabilitesBMEA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.40% over the past year.
EPS 1Y (TTM)40.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, BMEA will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.78% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y59.4%
EPS Next 2Y31.24%
EPS Next 3Y18.11%
EPS Next 5Y11.78%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BMEA Yearly Revenue VS EstimatesBMEA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2030 2031 2032 200M 400M 600M
BMEA Yearly EPS VS EstimatesBMEA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BMEA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BMEA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BMEA Price Earnings VS Forward Price EarningsBMEA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BMEA Per share dataBMEA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

BMEA's earnings are expected to grow with 18.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.24%
EPS Next 3Y18.11%

More info and screens

0

5. Dividend

5.1 Amount

BMEA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BIOMEA FUSION INC

NASDAQ:BMEA (12/12/2025, 8:16:12 PM)

Premarket: 1.44 +0.03 (+2.13%)

1.41

-0.11 (-7.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)03-31 2026-03-31/amc
Inst Owners32.04%
Inst Owner Change-12.48%
Ins Owners3.61%
Ins Owner Change3.17%
Market Cap99.69M
Revenue(TTM)N/A
Net Income(TTM)-95.71M
Analysts83.08
Price Target7.14 (406.38%)
Short Float %12.68%
Short Ratio3.87
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.15%
Min EPS beat(2)-3.47%
Max EPS beat(2)5.77%
EPS beat(4)2
Avg EPS beat(4)-3.03%
Min EPS beat(4)-28.2%
Max EPS beat(4)13.79%
EPS beat(8)4
Avg EPS beat(8)-2.58%
EPS beat(12)6
Avg EPS beat(12)-1.37%
EPS beat(16)7
Avg EPS beat(16)-2.92%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.64%
PT rev (3m)-3.92%
EPS NQ rev (1m)-5.94%
EPS NQ rev (3m)-10.75%
EPS NY rev (1m)1.57%
EPS NY rev (3m)4.52%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.38
P/tB 6.38
EV/EBITDA N/A
EPS(TTM)-2.39
EYN/A
EPS(NY)-1.07
Fwd EYN/A
FCF(TTM)-1.22
FCFYN/A
OCF(TTM)-1.22
OCFYN/A
SpS0
BVpS0.22
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -173.43%
ROE -612.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-98.37%
ROA(5y)-65.2%
ROE(3y)-137.7%
ROE(5y)-89.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.48%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.18
Quick Ratio 3.18
Altman-Z -15.22
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)130.81%
Cap/Depr(5y)432.09%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.4%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.33%
EPS Next Y59.4%
EPS Next 2Y31.24%
EPS Next 3Y18.11%
EPS Next 5Y11.78%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.32%
EBIT Next 3Y8.03%
EBIT Next 5Y1.14%
FCF growth 1Y11.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.01%
OCF growth 3YN/A
OCF growth 5YN/A

BIOMEA FUSION INC / BMEA FAQ

What is the fundamental rating for BMEA stock?

ChartMill assigns a fundamental rating of 2 / 10 to BMEA.


What is the valuation status for BMEA stock?

ChartMill assigns a valuation rating of 0 / 10 to BIOMEA FUSION INC (BMEA). This can be considered as Overvalued.


How profitable is BIOMEA FUSION INC (BMEA) stock?

BIOMEA FUSION INC (BMEA) has a profitability rating of 0 / 10.


What is the expected EPS growth for BIOMEA FUSION INC (BMEA) stock?

The Earnings per Share (EPS) of BIOMEA FUSION INC (BMEA) is expected to grow by 59.4% in the next year.